{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:15:25Z","timestamp":1780575325685,"version":"3.54.1"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tongue squamous cell carcinoma (TSCC) is a significant global health issue with high incidence and mortality rates. Current treatments involve surgery, radiotherapy, and chemotherapy; however, prognosis remains poor. Recent research highlights the crucial role of the tumor microenvironment, especially immune cells and checkpoints like PD-L1 and IDO, in TSCC progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study aims to investigate the expression of IDO and PD-L1 in TSCC patients before and after chemotherapy and their association with patients\u2019 clinicopathological characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This study involved 106 TSCC patients from Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&amp;amp;RC) in Pakistan, with biopsies obtained from 2012 to 2022. Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded (FFPE) tumor samples to evaluate IDO and PD-L1 expression before and after chemotherapy. Data on patient demographics, tumor characteristics, and treatment were collected, and follow-up continued until January 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort had a mean age of 48.9 years, with a predominance of male patients. Prior to chemotherapy, 83% of patients were IDO-negative, and 75.5% were PD-L1-negative. Post-chemotherapy, IDO expression increased to 24.5% of patients (n = 26), with 84.6% exhibiting low expression and 15.4% showing high expression. While PD-L1 expression was increased to 29.2% (n = 31), with 90.3% of the positive cases showing low expression and 9.7% high expression. IDO expression was notably higher in multifocal tumors and correlated with increased comorbidities post-chemotherapy. Despite changes in marker expression, there was no significant difference in survival rates associated with IDO or PD-L1 expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Chemotherapy appears to upregulate IDO and PD-L1 expressions in TSCC, highlighting the potential for integrating immunotherapy into treatment regimens. Further studies are needed to explore the dynamics of these biomarkers over time and their impact on patient outcomes, emphasizing the need for comprehensive therapeutic strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1495722","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T05:31:36Z","timestamp":1754976696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Expression of immune checkpoints (IDO and PD-L1) in oral tongue cancer patients: a 10-year retrospective cohort study in Pakistan"],"prefix":"10.3389","volume":"15","author":[{"given":"Merium","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaarif","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Atif","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alamgeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Abu Bakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Zafar","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Tahseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer Nisar","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Loya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2025.102234","article-title":"Associations of lifestyle factors with oral cancer risk: An umbrella review","volume":"126","author":"Xu","year":"2025","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"B2","volume-title":"Global Cancer Observatory: Cancer Today (version 1.1)","author":"Ferlay","year":"2020"},{"key":"B3","unstructured":"Ferlay\n              J\n            \n            \n              Ervik\n              M\n            \n            \n              Lam\n              F\n            \n            \n              Laversanne\n              M\n            \n            \n              Colombet\n              M\n            \n            \n              Mery\n              L\n            \n          \n          Lyon, France\n          International Agency for Research on Cancer\n          Global Cancer Observatory: Cancer Today\n          2024\n          2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2008.06.002","article-title":"Global epidemiology of oral and oropharyngeal cancer","volume":"45","author":"Warnakulasuriya","year":"2009","journal-title":"Oral Oncol"},{"key":"B5","article-title":"The role of supraomohyoid neck dissection in patients of oral cavity carcinoma","volume":"38","author":"Hao","year":"2002","journal-title":"Oral Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18456","DOI":"10.1038\/s41598-025-02094-9","article-title":"MCTP2 is a novel biomarker promoting tumor progression and nodal metastasis in oral squamous cell carcinoma","volume":"15","author":"Shimojukkoku","year":"2025","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1097\/01.cad.0000198913.75571.13","article-title":"Recent new approaches to the treatment of head and neck cancer","volume":"17","author":"St John","year":"2006","journal-title":"Anti-cancer Drugs"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2010.12.006","article-title":"Compartmental tongue surgery: long term oncologic results in the treatment of tongue cancer","volume":"47","author":"Calabrese","year":"2011","journal-title":"Oral Oncol"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1111\/odi.15009","article-title":"Web-based prognostic tools for oral tongue cancer: An analysis of online predictors","volume":"30","author":"Wahab","year":"2024","journal-title":"Oral Diseases"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052252","article-title":"New Insights Into Oral Squamous Cell Carcinoma: From Clinical Aspects to Molecular Tumorigenesis","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-3-030-59038-3_4","article-title":"The Microenvironment of Tongue Cancer","volume":"1296","author":"Tao","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1148\/radiol.2018181349","article-title":"Imaging of Cancer Immunotherapy: Current Approaches and Future Directions","volume":"290","author":"Nishino","year":"2019","journal-title":"Radiology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071937","article-title":"Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review","volume":"12","author":"Kujan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00606-3","article-title":"Immunohistochemical Study of PD-1\/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence","volume":"26","author":"Naruse","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapyPD-L1 IHC as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B22","article-title":"PD-L1 expression in tongue squamous cell carcinoma","volume":"54","author":"Akisada","year":"2021","journal-title":"Med Mol Morphol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-022-02264-x","article-title":"Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity","volume":"41","author":"Archilla-Ortega","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12967-022-03554-w","article-title":"IDO\/kynurenine pathway in cancer: possible therapeutic approaches","volume":"20","author":"Abd El-Fattah","year":"2022","journal-title":"J Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2002.01526.x","article-title":"Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division","volume":"107","author":"Lee","year":"2002","journal-title":"Immunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2671","article-title":"Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells","volume":"11","author":"Okamoto","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2011.03.007","article-title":"Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas","volume":"47","author":"Laimer","year":"2011","journal-title":"Oral Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12605","article-title":"Takasu Cet al. The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer","volume":"38","author":"Nishi","year":"2018","journal-title":"Anticancer Res"},{"key":"B35","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1200\/jco.2007.25.18_suppl.6073","article-title":"Cisplatin plus gemcitabine (GC) as induction chemotherapy in locally advanced head and neck cancer (HANC)","volume":"25","author":"Jamshed","year":"2007","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-008-0395-1","article-title":"Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma","volume":"134","author":"Pan","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000083","article-title":"Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors","volume":"1","author":"Igarashi","year":"2016","journal-title":"ESMO Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cre2.590","article-title":"PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside","volume":"8","author":"Nocini","year":"2022","journal-title":"Clin Exp Dent Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030710","article-title":"Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study","volume":"10","author":"Pe\u00f1a-Cardelles","year":"2022","journal-title":"Biomedicines"},{"key":"B40","doi-asserted-by":"crossref","first-page":"104460","DOI":"10.1016\/j.oraloncology.2019.104460","article-title":"Immunotherapy for head and neck cancer: Recent advances and future directions","volume":"99","author":"Cramer","year":"2019","journal-title":"Oral Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S398908","article-title":"IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages","volume":"16","author":"Chen","year":"2023","journal-title":"Int J Gen Med"},{"key":"B42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3892\/ol.2022.13493","article-title":"Prognostic implications of immune classification using IDO1 expression in extrahepatic bile duct carcinoma","volume":"24","author":"Noh","year":"2022","journal-title":"Oncol Lett"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1393-y","article-title":"Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry","volume":"62","author":"Soliman","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1724600819884722","article-title":"Expression of PD-1\/PD-L1 in head and neck squamous cell carcinoma and its clinical significance","volume":"34","author":"Chen","year":"2019","journal-title":"Int J Biol Markers"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41415-022-5166-x","article-title":"Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors","volume":"233","author":"Gormley","year":"2022","journal-title":"Br Dent J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.616629","article-title":"Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges","volume":"11","author":"Almangush","year":"2021","journal-title":"Front Oncol"},{"key":"B48","article-title":"Blockade of CCL2 expression overcomes intrinsic PD-1\/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer","volume":"10","author":"Choi","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000061","article-title":"Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Cancer J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12967-014-0373-0","article-title":"PD-1\/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation","volume":"13","author":"Ji","year":"2015","journal-title":"J Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.08.005","article-title":"Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR\/ERK Activation","volume":"11","author":"Ng","year":"2018","journal-title":"Transl Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci"},{"key":"B55","article-title":"Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk \/MAPK signaling pathway","author":"Qin","year":"2010","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008824","article-title":"Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression","volume":"4","author":"Bellucci","year":"2015","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2019.02.038","article-title":"IFN-\u03b3 Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer","volume":"240","author":"Imai","year":"2019","journal-title":"J Surg Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800630","article-title":"Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.531491","article-title":"IDO Expression in Cancer: Different Compartment, Different Functionality","author":"Meireson","year":"2020","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.12.029","article-title":"Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions","volume":"126","author":"Tomek","year":"2017","journal-title":"Eur J Med Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00551","article-title":"Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research","volume":"5","author":"Nguyen","year":"2014","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034785","article-title":"HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells","volume":"109","author":"Boasso","year":"2007","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4137\/IJTR.S26862","article-title":"Tryptophan Catabolism in Chronic Viral Infections: Handling Uninvited Guests","volume":"8","author":"Mehraj","year":"2015","journal-title":"Int J Tryptophan Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00673","article-title":"Cancer Immunotherapy by Targeting IDO1\/TDO and Their Downstream Effectors","volume":"5","author":"Platten","year":"2015","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4155\/fmc.14.151","article-title":"Research progress of indoleamine 2,3-dioxygenase inhibitors","volume":"7","author":"Jiang","year":"2015","journal-title":"Future Med Chem"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2174\/156800909790192374","article-title":"Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy","volume":"9","author":"Liu","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2007.04.010","article-title":"Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice","volume":"396","author":"Ball","year":"2007","journal-title":"Gene"},{"key":"B70","doi-asserted-by":"crossref","DOI":"10.3109\/00016489.2016.1152631","article-title":"The expression and prognostic relevance of indoleamine 2, 3-dioxygenase in tongue squamous cell carcinoma","volume":"136","author":"Sepp\u00e4l\u00e4","year":"2016","journal-title":"Acta Oto-Laryngologica"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106183","article-title":"Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck","volume":"135","author":"Park","year":"2022","journal-title":"Oral Oncol"},{"key":"B72","doi-asserted-by":"crossref","first-page":"938063","DOI":"10.3389\/fimmu.2022.938063","article-title":"The expression pattern of Immune checkpoints after chemo\/radiotherapy in the tumor microenvironment","volume":"13","author":"Hassanian","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154042","article-title":"PD-L1 expression in head and neck cancer tissue specimens decreases with time","volume":"237","author":"Karpathiou","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B74","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-319-67577-0_7","article-title":"Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment","volume":"1036","author":"Johnson","year":"2017","journal-title":"Adv Exp Med Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1495722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T05:31:39Z","timestamp":1754976699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1495722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":74,"alternative-id":["10.3389\/fonc.2025.1495722"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1495722","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"article-number":"1495722"}}